Streetbeat News

Regulatory

AAN

J Capital Research has issued a report questioning the go-private deal of The Aaron's Company (AAN), suggesting that the company might be concealing the true buyer. The report raises concerns about potential federal intervention in the deal.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 1:32 pm

RXRX

Recursion Pharmaceuticals (NASDAQ:RXRX) shares fell after announcing Phase 2 trial results for REC-994 in treating Cerebral Cavernous Malformation. While the trial met safety endpoints, no significant improvements in patient outcomes were observed at 12 months. The company plans further studies and discussions with the FDA.

Portfolio Pulse from Adam Eckert

September 03, 2024 | 1:28 pm

SMCI

Super Micro's CEO reassures customers and partners that the delay in its annual report filing and a short-seller report will not impact its product delivery or IT solution capabilities. The company expects no material changes in Q4 results, emphasizing strong financial performance and ongoing production.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 1:27 pm

AGBA

AGBA Group Holding Limited and Triller Corp. have announced an amended and restated merger agreement. The newly combined entity will trade on Nasdaq as 'Triller Group Inc.' with the ticker 'ILLR'. The merger aims to create an advanced social media and entertainment platform powered by AI and machine-learning technologies. The transaction is pending regulatory and shareholder approvals.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 1:19 pm

CYCC

Cyclacel Pharmaceuticals has filed an appeal against a Nasdaq staff delisting letter. The company is seeking to maintain its listing on the Nasdaq stock exchange.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 1:18 pm

EZFL

EzFill Holdings has regained compliance with Nasdaq's listing requirements, which is a positive development for the company and its investors.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 1:17 pm

ZYXI

Zynex has received FDA clearance for its TensWave device, which is a significant milestone for the company. This approval could enhance Zynex's product offerings and potentially boost its market position.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 1:17 pm

HAL

IEZ

PXJ

Halliburton's stock is falling due to a cyber attack that disrupted critical business applications. The company is assessing the breach's impact but expects no significant financial harm. However, risks like management distractions and regulatory scrutiny remain.

Portfolio Pulse from Nabaparna Bhattacharya

September 03, 2024 | 1:16 pm

LGVN

Longeveron has announced a Type C meeting with the FDA regarding the pathway to a Biological License Application (BLA) for Lomecel-B in treating Hypoplastic Left Heart Syndrome. The ongoing Phase 2b clinical trial, ELPIS II, is considered pivotal for potential full approval.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 1:03 pm

GOOG

GOOGL

JPMorgan analyst Doug Anmuth warns that the DOJ trial against Alphabet Inc (Google) could negatively impact Google's earnings by up to 10%, with potential outcomes including opening up search distribution channels to competitors. The trial could lead to significant changes in Google's business model, affecting its core operations.

Portfolio Pulse from Surbhi Jain

September 03, 2024 | 12:56 pm